☆ 4.6 Editorial Material

Multi-target angiokinase inhibitors to fight resistance

CELL CYCLE (2014)

Journal

CELL CYCLE

Volume 13, Issue 17, Pages 2649-2650

Publisher

LANDES BIOSCIENCE

DOI: 10.4161/15384101.2014.954216

Keywords

-

Categories

Cell Biology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Chemistry, Medicinal

BDDE-Inspired Chalcone Derivatives to Fight Bacterial and Fungal Infections

Ana Jesus, Fernando Duraes, Nikoletta Szemeredi, Joana Freitas-Silva, Paulo Martins da Costa, Eugenia Pinto, Madalena Pinto, Gabriella Spengler, Emilia Sousa, Honorina Cidade

Summary: The growing number of infectious diseases around the world threatens the effectiveness of antibiotics and contributes to the global health problem of antibiotic resistance. Researchers have discovered a series of compounds with antimicrobial activity and potential to combat antibiotic resistance. Some of these compounds show promising activity against fungi and bacteria, without causing cytotoxicity.

MARINE DRUGS (2022)

Add to Collection

News Item Biochemistry & Molecular Biology

How to fight antibiotic resistance

Mike May

Summary: Researchers utilize AI and bioinformatics for finding novel antimicrobials, while governments experiment with financial incentives for pharmaceutical companies.

NATURE MEDICINE (2023)

Add to Collection

Article Engineering, Biomedical

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy

Wenjing Xu, Chunping Ye, Xin Qing, Shengli Liu, Xinyi Lv, Wenjun Wang, Xiaochen Dong, Yewei Zhang

Summary: Multi-target Tyrosine Kinase Inhibitors (MTKIs) have gained significant attention in tumor therapy due to their ability to inhibit tumor cell proliferation. However, their toxicity and drug resistance have limited their clinical application. In recent years, nano pharmaceutical technology has been used to deliver MTKIs through various types of nanocarriers, overcoming drug resistance and improving therapeutic efficiency.

MATERIALS TODAY BIO (2022)

Add to Collection

Review Multidisciplinary Sciences

Sulfated polysaccharides as multi target molecules to fight COVID 19 and comorbidities

Enrique Javier Carvajal-Barriga, R. Douglas Fields

Summary: The majority of research focuses on the adaptive immune system in combating SARS-CoV-2 infection, but innate immunity plays an equally important role in understanding and controlling infectious diseases. Sulfated polysaccharides, specifically extracellular polysaccharides, have been found to effectively block and deactivate bacteria, fungi, and viruses, including SARS-CoV-2. They have significant potential as immunomodulators, antioxidants, antitumors, anticoagulants, antibacterial agents, and potent antivirals. Their interactions with immune cell signaling, oxidative reactions, cytokine signaling, receptor binding, and viral and bacterial toxicity suggest their potential for the development of novel therapeutic treatments for SARS-CoV-2 and other infectious diseases.

HELIYON (2023)

Add to Collection

Review Nanoscience & Nanotechnology

Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors

Qinqin Xu, Xinyue Lan, Huimin Lin, Qiye Xi, Manchun Wang, Xiaolong Quan, Guangyu Yao, Zhiqiang Yu, Yongxia Wang, Meng Yu

Summary: The tumor microenvironment (TME) plays a crucial role in the drug resistance of tumor cells. Understanding and modulating the TME is important for enhancing the efficacy of anti-drug-resistant tumor therapy. This review focuses on the relationships between specific TME characteristics and drug resistance in tumor treatments, as well as the exciting antitumor activities strengthened by TME regulation through nanomedicine design.

WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Nanomedicine to fight infectious disease

Kathryn M. Rubey, Jacob S. Brenner

Summary: The ubiquity and potency of antibiotics may give a false impression that infection is a solved problem. However, bacterial infections remain a major cause of illness and death. The use of systemic antibiotics can lead to destruction of the gut microbiome and increase the risk of infections, while the rise of multi-drug resistant microorganisms poses a growing threat to treatment.

ADVANCED DRUG DELIVERY REVIEWS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Arf6 as a therapeutic target: Structure, mechanism, and inhibitors

Dejuan Sun, Yuanyuan Guo, Piyu Tang, Hua Li, Lixia Chen

Summary: ADP-ribosylation factor 6 (Arf6), a small G-protein, plays important roles in cellular events and cancer progression. Understanding its function and mechanism is essential for future cancer therapy. This review summarizes the structure and roles of Arf6 in cancer, and discusses its potential as a target for protein-protein interaction inhibitors.

ACTA PHARMACEUTICA SINICA B (2023)

Add to Collection

Article Chemistry, Multidisciplinary

Hesperidin Targets Leishmania donovani Sterol C-24 Reductase to Fight against Leishmaniasis

Shams Tabrez, Fazlur Rahman, Rahat Ali, Sajjadul Kadir Akand, Mohammed A. Alaidarous, Saeed Banawas, Abdul Aziz Bin Dukhyil, Abdur Rub

Summary: Hesperidin, a naturally occurring flavanoid found in citrus fruits, showed significant antileishmanial activity by inducing apoptosis and inhibiting a specific enzyme in the parasite. This research could contribute to the development of a cost-effective and more effective drug for leishmaniasis.

ACS OMEGA (2021)

Add to Collection

Review Pharmacology & Pharmacy

Antibiotic Potentiation of Natural Products: A Promising Target to Fight Pathogenic Bacteria

Nabeelah Bibi Sadeer, Mohamad Fawzi Mahomoodally

Summary: Pathogenic microorganisms pose a major threat to human health, with increasing bacterial resistance leading to a rise in deaths from bacterial infections. Combining natural products with antibiotics has been shown to prolong the lifespan of existing antibiotics and reduce the impact of antibiotic resistance.

CURRENT DRUG TARGETS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Antimicrobial Peptides and Cationic Nanoparticles: A Broad-Spectrum Weapon to Fight Multi-Drug Resistance Not Only in Bacteria

Giulia E. Valenti, Silvana Alfei, Debora Caviglia, Cinzia Domenicotti, Barbara Marengo

Summary: With the increasing antibiotic and anticancer drug resistance, finding therapeutic strategies to combat multi-drug resistance has become crucial. This review provides a critical overview of innovative tools available to fight multi-drug resistance and discusses the potential use of nanoparticles and peptide mimetics.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Pharmacology & Pharmacy

Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma

Vincent Sauzeau, Julien Beignet, Christian Bailly, Gerard Vergoten

Summary: Despite advancements in targeted and immunotherapies, hepatocellular carcinoma (HCC) patients still face poor prognosis, especially in advanced and metastatic forms. Drug resistance, particularly in chemo-, targeted- and immuno-therapies, poses a significant challenge in the treatment of HCC. This article discusses the crucial role of the small GTPase Rac1 in HCC development and progression, along with its protein partners, and explores the potential of RNA-based regulators and small molecules to target Rac1. The oncogenic functions of Rac1 in HCC are highlighted, emphasizing its contribution to aggressive disease behavior such as cancer cell proliferation, tumor metastasis, and treatment resistance. Small molecule targeting of Rac1 has shown anticancer effects in experimental models of HCC. Rac1-binding agents like EHT 1864 and analogues offer new possibilities in combating HCC. The article addresses different approaches to inhibit Rac1 overactivation in HCC using small molecules, in combination with reference drugs, to induce cancer cell death and suppress cell invasion. It emphasizes the need to combine Rac1-targeted therapy with appropriate biomarkers for the selection of Rac1-activated tumors. The analysis underscores Rac1 as a potential target to overcome acquired and intrinsic resistance in HCC tumors and their metastatic potential.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Target and nontarget mechanisms of AHAS inhibitor cross-resistance patterns in Cyperus difformis

Alex R. Ceseski, Amar S. Godar, Sara Ohadi, Kassim Al-Khatib

Summary: Weed resistance to acetohydroxyacid synthase (AHAS) inhibiting herbicides has become a major issue for rice growers worldwide since the early 1990s. In California, resistance to bensulfuron-methyl was first observed in Cyperus difformis in 1993, and since then, resistance to at least one AHAS inhibitor has been reported in most major rice weeds. This study investigated the magnitude and mechanisms of AHAS inhibitor cross-resistance in California populations of C. difformis, identifying six major patterns of cross-resistance and confirming the presence of both target-site and metabolic resistance.

PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells

Ji-Hea Kim, Seung-Jin Lee, Ka-Won Kang, Byung-Hyun Lee, Yong Park, Byung-Soo Kim

Summary: The study shows that inhibiting the CXCR2-mTOR-c-Myc cascade has significant therapeutic effects in overcoming both TKI-sensitive and TKI-insensitive CML. The CXCR2 antagonist SB225002 demonstrates promising results in treating TKI-resistant CML patients.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Article Biochemical Research Methods

Can allele-specific loop-mediated isothermal amplification be used for rapid detection of target-site herbicide resistance in Lolium spp.?

Silvia Panozzo, Silvia Farinati, Maurizio Sattin, Laura Scarabel

Summary: In this study, the AS-LAMP technique was used to detect herbicide resistance in Lolium spp. The method showed good results in detecting ACCase gene, but had limitations when applied to ALS gene.

PLANT METHODS (2023)

Add to Collection

Article Computer Science, Information Systems

Robust Multi-Drone Multi-Target Tracking to Resolve Target Occlusion: A Benchmark

Zhihao Liu, Yuanyuan Shang, Timing Li, Guanlin Chen, Yu Wang, Qinghua Hu, Pengfei Zhu

Summary: Multi-drone multi-target tracking aims to detect and track targets across multiple drones and associate their identities, overcoming the limitations of single-drone object tracking. In this study, we introduce a novel occlusion-aware multi-drone multi-target tracking dataset called MDMT. It consists of 88 video sequences with 39,678 frames and includes 11,454 different IDs of persons, bicycles, and cars. We also propose a Multi-matching Identity Authentication network (MIA-Net) that effectively addresses the challenges of identity association and target occlusion in multi-drone multi-target tracking.

IEEE TRANSACTIONS ON MULTIMEDIA (2023)

Add to Collection

Article Oncology

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

T. Yoshino, D. C. Portnoy, R. Obermannova, G. Bodoky, J. Prausova, R. Garcia-Carbonero, T. Ciuleanu, P. Garcia-Alfonso, A. L. Cohn, E. Van Cutsem, K. Yamazaki, S. Lonardi, K. Muro, T. W. Kim, K. Yamaguchi, A. Grothey, J. O'Connor, J. Taieb, S. R. Wijayawardana, R. R. Hozak, F. Nasroulah, J. Tabernero

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna Bendel, Guillem Argiles, Niofi C. Tebbutt, Mafia Di Bartolomeo, Alfredo Falcone, Marwan Fakih, Mark Kozloff, Neil H. Segal, Alberto Sobrero, Yibing Yan, Llsung Chang, Anne Uyei, Louise Roberts, Fortunato Ciardieffo

LANCET ONCOLOGY (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

Teresa Macarulla, Clara Montagut, Francisco Javier Sanchez-Martin, Monica Granja, Helena Verdaguer, Javier Sastre, Josep Tabernero

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors

Lene Alifrangis, Rik Schoemaker, Niels J. Skartved, Rikke Hald, Clara Montagut, Scott Kopetz, Josep Tabernero, Michael Kragh, Janet R. Wade

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy Subgroup Analyses of a Randomized Clinical Trial

David H. Ilson, Josep Tabernero, Aliaksandr Prokharau, Hendrik-Tobias Arkenau, Michele Ghidini, Kazumasa Fujitani, Eric Van Cutsem, Peter Thuss-Patience, Giordano D. Beretta, Wasat Mansoor, Edvard Zhavrid, Maria Alsina, Ben George, Daniel Catenacci, Sandra McGuigan, Lukas Makris, Toshihiko Doi, Kohei Shitara

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma

Luis Palomero, Lubomir Bodnar, Francesca Mateo, Carmen Herranz-Ors, Roderic Espin, Mar Garcia-Varelo, Marzena Jesiotr, Gorka Ruiz de Garibay, Oriol Casanovas, Jose Lopez, Miquel Angel Pujana

CANCERS (2020)

Add to Collection

Article Genetics & Heredity

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael W. Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra Scherer, Matthew H. Bailey, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Yuanxin Xi, Jing Wang, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Vito W. Rebecca, Hua Sun, R. Jay Mashl, Sherri R. Davies, Ryan Jeon, Christian Frech, Jelena Randjelovic, Jacqueline Rosains, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C. O'Farrell, Elodie Modave, Diether Lambrechts, Petra ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Hyunsoo Kim, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A. Dean, Brandi Davis-Dusenbery, Yvonne A. Evrard, James H. Doroshow, Alana L. Welm, Bryan E. Welm, Michael T. Lewis, Bingliang Fang, Jack A. Roth, Funda Meric-Bernstam, Meenhard Herlyn, Michael A. Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Claudio Isella, Jeffrey A. Moscow, Livio Trusolino, Annette T. Byrne, Jos Jonkers, Carol J. Bult, Enzo Medico, Jeffrey H. Chuang

Summary: The analysis of copy number alterations in patient-derived xenografts (PDXs) and matched patient tumor samples reveals strong conservation of copy number alterations from patient tumors through late-passage PDXs, without systematic evolution driven by the mouse host. This suggests that PDX models are accurate in representing human cancer and that the mouse host does not significantly impact the copy number alterations during tumor evolution within the PDX model.

NATURE GENETICS (2021)

Add to Collection

Article Oncology

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond

Maria Alsina, Josep Tabernero, Marc Diez

Summary: Gastric cancer is a global healthcare problem with multiple symptoms and fragility in patients. Multidisciplinary teams are required for palliative care and nutritional support. Sequential treatment is the best approach, and a third-line treatment can improve survival and quality of life.

CANCERS (2022)

Add to Collection

Article Oncology

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

Chiara Bellio, Marta Emperador, Pol Castellano, Albert Gris-Oliver, Francesc Canals, Alex Sanchez-Pla, Esther Zamora, Joaquin Arribas, Cristina Saura, Violeta Serra, Josep Tabernero, Bruce A. Littlefield, Josep Villanueva

Summary: Drug tolerant persister (DTP) cells enter a reversible slow-cycling state after treatment, with GDF15 identified as a key protein over-secreted and essential for their survival. Combining eribulin with an anti-GDF15 antibody may be effective in targeting and killing breast cancer DTP cells.

CANCERS (2022)

Add to Collection

Review Oncology

Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications

Nadia Saoudi Gonzalez, Francesc Salva, Javier Ros, Iosune Baraibar, Marta Rodriguez-Castells, Ariadna Garcia, Adriana Alcaraz, Sharela Vega, Sergio Bueno, Josep Tabernero, Elena Elez

Summary: Metastatic colorectal cancer is a complex and life-threatening disease influenced by various factors. Tumor heterogeneity, caused by genetic and non-genetic factors, affects tumor development and therapy effectiveness. Computational analysis of next-generation sequencing and real-time monitoring of circulating tumor DNA are valuable tools in understanding tumor evolution and heterogeneity.

CANCERS (2023)

Add to Collection

Article Medicine, Research & Experimental

Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits

Lidia Moserle, Roser Pons, Mar Martinez-Lozano, Gabriela A. Jimenez-Valerio, August Vidal, Cristina Suarez, Enrique Trilla, Jose Jimenez, Ines de Torres, Joan Carles, Jordi Senserrich, Susana Aguilar, Luis Palomero, Alberto Amadori, Oriol Casanovas

EMBO MOLECULAR MEDICINE (2020)

Add to Collection

Meeting Abstract Oncology

BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer

Jayesh Desai, Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Fortunato Ciardello, Ashwin Gollerkeri, Kati Maharry, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, Pilar Garcia Alfonso, Timothy Price, Andrew Strickland, Niall Tebbutt, Christos Karapetis, Lorraine Chantrill, Felicity Murphy, Victor Sandor, Janna Christy-Bittel, Lisa Anderson, Josep Tabernero

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

J. Tabernero, A. Grothey, E. Van Cutsem, R. Yaeger, H. Wasan, T. Yoshino, J. Desai, F. Ciardiello, F. Loupakis, Y. Sang Hong, N. Steeghs, T. K. Guren, H-T. Arkenau, P. Garcia-Alfonso, A. Gollerkeri, M. Pickard, K. Maharry, J. L. Christy-Bittel, L. Anderson, S. Kopetz

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

Rosa Giuliani, Josep Tabernero, Fatima Cardoso, Keith Hanson McGregor, Malvika Vyas, Elisabeth G. E. de Vries

ESMO OPEN (2019)

Add to Collection

Correction Oncology

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFRTherapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial (vol 4, e175245, 2018)

Clara Montagut, Guillem Argiles, Fortunato Ciardiello, Thomas T. Poulsen, Rodrigo Dienstmann, Michael Kragh, Scott Kopetz, Trine Lindsted, Cliff Ding, Joana Vidal, Jenifer Clausell-Tormos, Giulia Siravegna, Francisco J. Sanchez-Martín, Klaus Koefoed, Mikkel W. Pedersen, Michael M. Grandal, Mikhail Dvorkin, Lucjan Wyrwicz, Ana Rovira, Antonio Cubillo, Ramon Salazar, Francoise Desseigne, Cristina Nadal, Joan Albanell, Vittorina Zagonel, Salvatore Siena, Guglielmo Fumi, Giuseppe Rospo, Paul Nadler, Ivan D. Horak, Alberto Bardelli, Josep Tabernero

JAMA ONCOLOGY (2019)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.